Back to base pairs: What is the genetic risk for red bloodcell alloimmunization?

Gerritsma, Jorn J.; Oomen, Ilja; Meinderts, Sanne M.; Schoot, C. Ellen van der; Biemond, Bart J.; Bom, Johanna G. van der; Fijnvandraat, Karin; Beers, Eduard J. van; Beijlevelt, M.; Brons, Paul; Cnossen, Marjon H.; Dovern, L.; Heijboer, H.; Hofstede, F.; Kerkhoffs, J.L.; Nur, Erfan; Ootjers, Claudia S.; Pagter, P.J. de; Rijneveld, Anita W.; Schols, Saskia E. M.; Smiers, Frans J.; Suiker, M.H.; Teuben, Sonja A.M.C.; Tuijn, Charlotte F.J. Van; Vliet, Ineke van; Zwagemaker, E.

doi:10.1016/j.blre.2020.100794

Cited by 8 publications

(1 citation statement)

References 60 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[ 3 , 4 ]. As a result, RBC alloimmunization can complicate the selection of future compatible transfusion units and furthermore, increase the risk of haemolytic transfusion reactions (HTRs), and the development of additional RBC alloantibodies and autoantibodies in subsequent transfusions [ 6 , 7 , 8 ].…”

Section: Introductionmentioning

confidence: 99%

HLA Class II regulation of immune response in sickle cell disease patients: Susceptibility to red blood cell alloimmunization (systematic review and meta‐analysis)

2022

View full text Add to dashboard Cite

Background and Objectives Sickle cell disease (SCD) patients are commonly treated with red blood cell (RBC) transfusion. Pretransfusion tests commonly involve limited serological antibody testing. RBC alloimmunization to RBC antigens is a frequently encountered complication seen in chronically transfused patients. Genetic factors such as the human leukocyte antigen (HLA) are known to influence and regulate immune responses. HLAs are highly polymorphic and play an essential role in regulating immune responses, including RBC alloimmunization. The aim of this study was to conduct a systematic review and meta‐analysis to evaluate the association between HLA Class II allelic polymorphisms with the possible risk of developing RBC alloantibodies. Materials and Methods Four databases were systematically searched for relevant studies between the years 2000 and 2021 following the PRISMA guidelines. Four articles met the eligibility and quality criterion, and three alleles, HLA‐DRB1*04, HLA‐DRB1*15 and HLA‐DQB1*03, that were found to be potentially associated with an increased risk in alloantibody formation were included. Results The primary outcome measure was alloimmunization by RBC antigen exposure in multiply transfused SCD patients. The total estimate of alloimmunization of the SCD patients was 2.33 (95% CI, 1.58–3.44), demonstrating susceptibility to RBC alloantibody formation. Heterogeneity between the studies was insignificant, suggesting the differences associated with random sampling errors. The results showed that SCD patients carry an increased risk of producing RBC alloantibodies. Conclusion A strategy to prevent RBC alloimmunization is genotyping for genetically susceptible SCD patients receiving multiple transfusions. Early identification of genetic variants that can potentially increase the risk of RBC alloimmunization could aid in the screening process and selection of phenotypically matched RBC units.

show abstract